Orchestra BioMed (NASDAQ:OBIO) Issues Quarterly Earnings Results

Orchestra BioMed (NASDAQ:OBIO) released its quarterly earnings data on Monday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03), Zacks reports. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.

Orchestra BioMed Price Performance

OBIO traded up $0.22 on Monday, hitting $4.46. 154,400 shares of the stock were exchanged, compared to its average volume of 252,622. The firm has a market capitalization of $267.06 million, a price-to-earnings ratio of -4.60 and a beta of 0.50. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. Orchestra BioMed has a 12 month low of $2.20 and a 12 month high of $5.42. The business has a 50-day moving average of $3.97 and a two-hundred day moving average of $4.10.

Analyst Upgrades and Downgrades

OBIO has been the topic of several research reports. Wall Street Zen downgraded Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Barclays boosted their price target on Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Orchestra BioMed in a report on Friday, July 17th. B. Riley Financial reduced their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.60.

Insider Buying and Selling at Orchestra BioMed

In other news, Director Eric S. Fain purchased 20,000 shares of Orchestra BioMed stock in a transaction that occurred on Thursday, May 14th. The shares were acquired at an average price of $4.13 per share, for a total transaction of $82,600.00. Following the transaction, the director owned 91,709 shares of the company’s stock, valued at approximately $378,758.17. The trade was a 27.89% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Darren Sherman sold 15,000 shares of Orchestra BioMed stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the completion of the transaction, the insider directly owned 1,154,327 shares in the company, valued at $4,721,197.43. This trade represents a 1.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have bought a total of 39,636 shares of company stock valued at $158,081 in the last ninety days. 7.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Orchestra BioMed

Several institutional investors and hedge funds have recently added to or reduced their stakes in OBIO. Alyeska Investment Group L.P. bought a new stake in shares of Orchestra BioMed during the 3rd quarter worth $3,386,000. Pathstone Holdings LLC bought a new position in Orchestra BioMed in the third quarter valued at about $2,495,000. Vanguard Group Inc. grew its position in Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after acquiring an additional 324,558 shares during the last quarter. Marshall Wace LLP acquired a new position in Orchestra BioMed during the fourth quarter worth about $712,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Orchestra BioMed by 467.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 134,073 shares of the company’s stock worth $556,000 after acquiring an additional 110,443 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.